• 1
    Capelle L, Oei P, Teoh H et al. Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 2009; 53: 3059.
  • 2
    Hoang-Xuan K, He J, Huguet S et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001; 57: 127881.
  • 3
    Ramirez C, Bowman C, Maurage CA et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors – towards individualized tumor treatment? Neuro Oncol 2010; 12: 4909.
  • 4
    Botting RA, McLachlan CS. Does cellular heterogeneity influence neuroblastoma cell line proliferation and invasiveness with granulocyte colony-stimulating factor? J Pediatr Surg 2009; 44: 24367.
  • 5
    Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol 2009; 11: 3117.
  • 6
    Feiden S, Feiden W. WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing and grading of common-type diffuse gliomas. Pathologe 2008; 29: 41121.
  • 7
    Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK et al. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 2008; 132: 9931007.
  • 8
    Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97109.
  • 9
    Davis FG, Malmer BS, Aldape K et al. Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17: 4849.
  • 10
    Abrey LE, Louis DN, Paleologos N et al.Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007; 9: 3148.
  • 11
    Scheie D, Cvancarova M, Mørk S et al. Can morphology predict 1p/19q loss in oligodendroglial tumours? Histopathology 2008; 53: 57887.
  • 12
    Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res 2009; 9: 131 (Abstract) doi:10.1186/1472-6963-9-131.
  • 13
    Romberger C. Oligodendroglioma: a riddle inside a misnomer wrapped in an enigma The oligoemperor has no clothes! J Lanc Gen Hosp 2011; 6: 247.
  • 14
    Bigner DD, McClendon RE, Bruner JM (eds). Russell and Rubinstein's Pathology of Tumors of the Nervous System, 6th edn. Oxford University Press, New York 1998.
  • 15
    Gupta M, Djalilvand A, Brat DJ. Clarifying the diffuse gliomas: oligodendroglioma. Am J Clin Pathol 2005; 124: 75568.
  • 16
    Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007; 131: 24251.
  • 17
    Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010; 6: 695701.
  • 18
    Ueki K, Nishikawa R, Nakazato Y et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196201.
  • 19
    Riemenschneider MJ, Reifenberger G. Molecular neuropathology of gliomas. Int J Mol Sci 2009; 10: 184212.
  • 20
    Gozé C, Rigau V, Gibert L, Maudelonde T, Duffau H. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol 2009; 91: 15.
  • 21
    Kapoor GS, Gocke TA, Chawla S et al. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009; 92: 37386.
  • 22
    Marko NF, Prayson RA, Barnett GH, Weil RJ. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study. Genomics 2010; 95: 1624.